Cytokinetics Inc

-0.40 (-1.07%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.11B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.38 Million
Adjusted EPS-$0.89
See more estimates
10-Day MA$37.71
50-Day MA$37.66
200-Day MA$28.62
See more pivots

Cytokinetics Inc Stock, NASDAQ:CYTK

280 East Grand Avenue, South San Francisco, California 94080
Phone: +1.650.624.3000
Number of Employees: 184


Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.